Advaxis, Inc. (ADXS) Starts Presentation at LD Micro Conference

Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology.  The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to generate cancer fighting T-cells and myeloid-derived suppressor cells (MDSCs).  For more information, visit the company’s website at www.advaxis.com.